PubTransformer

A site to transform Pubmed publications into these bibliographic reference formats: ADS, BibTeX, EndNote, ISI used by the Web of Knowledge, RIS, MEDLINE, Microsoft's Word 2007 XML.

The association between biochemical control and cardiovascular risk factors in acromegaly.

Abstract The study aim was to estimate the proportion of acromegaly patients with various comorbidities and to determine if biochemical control was associated with reduced proportion of cardiovascular risk factors.
PMID
Related Publications

Acromegaly and pregnancy: a retrospective multicenter study of 59 pregnancies in 46 women.

Cardiac risk in patients with treatment naïve, first-line medically controlled and first-line surgically cured acromegaly in comparison to matched data from the general population.

Challenges in the diagnosis and management of acromegaly: a focus on comorbidities.

Acromegaly: presentation, morbidity and treatment outcomes at a single centre.

Acromegaly.

Authors

Mayor MeshTerms
Keywords

Acromegaly

Biochemical control

Chart review

Comorbidities

Patient registry

Journal Title bmc endocrine disorders
Publication Year Start




PMID- 28279153
OWN - NLM
STAT- MEDLINE
DA  - 20170310
DCOM- 20170314
LR  - 20170315
IS  - 1472-6823 (Electronic)
IS  - 1472-6823 (Linking)
VI  - 17
IP  - 1
DP  - 2017 Mar 09
TI  - The association between biochemical control and cardiovascular risk factors in
      acromegaly.
PG  - 15
LID - 10.1186/s12902-017-0166-6 [doi]
AB  - BACKGROUND: The study aim was to estimate the proportion of acromegaly patients
      with various comorbidities and to determine if biochemical control was associated
      with reduced proportion of cardiovascular risk factors. METHODS: Data were from a
      single-center acromegaly registry. Study patients were followed for >/=12 months 
      after initial treatment. Study period was from first to last insulin-like growth 
      factor-I and growth hormone tests. RESULTS: Of 121 patients, 55% were female.
      Mean age at diagnosis was 42.4 (SD: 15.0). Mean study period was 8.8 (SD: 7.2)
      years. Macroadenomas were observed in 93 of 106 patients (87.7%), and
      microadenomas in 13 (12.3%). Initial treatment was surgery in 104 patients (86%),
      pharmacotherapy in 16 (13.2%), and radiation therapy in 1 (0.8%). Of 120
      patients, 79 (65.8%) achieved control during the study period. New onset
      comorbidities (reported 6 months after study start) were uncommon (<10%).
      Comorbidities were typically more prevalent in uncontrolled versus controlled
      patients-24 (58.5%) vs. 33 (41.8%) had hypertension, 17 (41.5%) vs. 20 (25.3%)
      had diabetes, 11 (26.8%) vs. 16 (20.3%) had sleep apnea, and 3 (7.3%) vs. 3
      (3.8%) had cardiomyopathy-except for colon polyps or cancer (19.5% vs. 20.3%),
      left ventricular hypertrophy (9.8% vs. 11.4%), and visual defects (14.6% vs.
      17.7%). CONCLUSIONS: A greater number of comorbidities were observed in
      biochemically uncontrolled patients with acromegaly compared to their controlled 
      counterparts in this single-center registry. About a third of the patients
      remained uncontrolled after a mean of >8 years of treatment, demonstrating the
      difficulty of achieving control in some patients.
FAU - Carmichael, John D
AU  - Carmichael JD
AD  - Cedars-Sinai Medical Center, 8700 Beverly Blvd, Los Angeles, CA, 90048, USA.
FAU - Broder, Michael S
AU  - Broder MS
AD  - Partnership for Health Analytic Research, LLC, 280 S. Beverly Dr., Suite 404,
      Beverly Hills, CA, 90212, USA.
FAU - Cherepanov, Dasha
AU  - Cherepanov D
AD  - Partnership for Health Analytic Research, LLC, 280 S. Beverly Dr., Suite 404,
      Beverly Hills, CA, 90212, USA. [email protected]
FAU - Chang, Eunice
AU  - Chang E
AD  - Partnership for Health Analytic Research, LLC, 280 S. Beverly Dr., Suite 404,
      Beverly Hills, CA, 90212, USA.
FAU - Mamelak, Adam
AU  - Mamelak A
AD  - Cedars-Sinai Medical Center, 8700 Beverly Blvd, Los Angeles, CA, 90048, USA.
FAU - Said, Qayyim
AU  - Said Q
AD  - Novartis Pharmaceuticals Corporation, One Health Plaza, East Hanover, NJ,
      07936-1080, USA.
FAU - Neary, Maureen P
AU  - Neary MP
AD  - Novartis Pharmaceuticals Corporation, One Health Plaza, East Hanover, NJ,
      07936-1080, USA.
FAU - Bonert, Vivien
AU  - Bonert V
AD  - Cedars-Sinai Medical Center, 8700 Beverly Blvd, Los Angeles, CA, 90048, USA.
LA  - eng
PT  - Journal Article
DEP - 20170309
PL  - England
TA  - BMC Endocr Disord
JT  - BMC endocrine disorders
JID - 101088676
SB  - IM
MH  - Acromegaly/*complications/therapy
MH  - Adenoma/*complications/therapy
MH  - Adult
MH  - Cardiovascular Diseases/diagnosis/*etiology
MH  - Combined Modality Therapy/*adverse effects
MH  - Female
MH  - Follow-Up Studies
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Prognosis
MH  - Prospective Studies
MH  - Risk Factors
PMC - PMC5345253
OTO - NOTNLM
OT  - Acromegaly
OT  - Biochemical control
OT  - Chart review
OT  - Comorbidities
OT  - Patient registry
EDAT- 2017/03/11 06:00
MHDA- 2017/03/16 06:00
CRDT- 2017/03/11 06:00
PHST- 2016/11/16 [received]
PHST- 2017/03/02 [accepted]
AID - 10.1186/s12902-017-0166-6 [doi]
AID - 10.1186/s12902-017-0166-6 [pii]
PST - epublish
SO  - BMC Endocr Disord. 2017 Mar 9;17(1):15. doi: 10.1186/s12902-017-0166-6.

<?xml version="1.0" encoding="UTF-8"?>
<b:Sources SelectedStyle="" xmlns:b="http://schemas.openxmlformats.org/officeDocument/2006/bibliography"  xmlns="http://schemas.openxmlformats.org/officeDocument/2006/bibliography" >
</b:Sources>